Overview

Ma-Spore ALL 2020 Study

Status:
RECRUITING
Trial end date:
2030-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is to improve the overall survival rate of children and young adult with B-lineage acute lymphoblastic leukemia (B-ALL) in Singapore and Malaysia in the context of a multicenter cooperative trial using a risk-stratified therapy.
Phase:
PHASE2
Details
Lead Sponsor:
National University Hospital, Singapore
Treatments:
Asparaginase
Cyclophosphamide
Cytarabine
Dasatinib
Dexamethasone
Doxorubicin
fludarabine
Imatinib Mesylate
Mercaptopurine
Methotrexate
pegaspargase
Prednisolone
Rituximab
Thioguanine
Vincristine